Relapse-free survival in Sudanese women with non-metastatic breast cancer
- PMID: 37637030
- PMCID: PMC10445990
- DOI: 10.1016/j.gloepi.2022.100082
Relapse-free survival in Sudanese women with non-metastatic breast cancer
Abstract
Background: Breast cancer (BC) is the most frequently diagnosed cancer and a major cause of cancer mortality in Sudan. However, there is lack of data related to BC relapse. Therefore, this study was undertaken to estimate the 5-year relapse free survival (RFS) rate and factors related to BC relapse in Sudanese women with non-metastatic BC.
Methods: Data of BC women with BC diagnosed and treated at the National Cancer Institute-University of Gezira during 2012 were retrieved from medical records. The cases were followed-up through hospital records and telephone contact. Survival functions were calculated using Kaplan-Meier method and compared by log-rank test. The prognostic factors were tested using univariate and multivariable Cox regression analyses.
Results: We included 168 women with median age of 45 years (range, 22-83 years). 53.5%of women had stage III at time of diagnosis, whereas 4.2% and 42.3% of women presented with stage I and stage II, respectively. At the end of 5 years follow-up, with median follow-up period of 64 months, 94 (56.0%) women were alive in remission, 11 (6.5%) were alive with BC relapse, 49 (29.2%) were dead, and survival status was unknown in 14 (8.3%) women. Most of the occurred relapses were distant relapses. The 5-year RFS was 59%. The independent predictors of relapse were: larger primary tumor size (HR:1.84, 95% CI: 1.54-5.48, p=0.018); involved axillary lymph nodes with tumour (HR: 2.91, 95% CI: 1.53-7.91, p=0.001); not receiving adjuvant radiotherapy (HR: 2.2, 95% CI: 1.22-3.95, p=0.009); and not receiving hormone therapy (HR: 1.67, 95% CI: 1.01-2.76, p= 0.046).
Conclusion: We found a high risk of BC relapse in our resource-constrained settings. Advanced stages, not receiving adjuvant radiotherapy, and not receiving adjuvant hormone therapy were independent predictors associated with worse 5-year RFS. Therefore, enhancing the early diagnosis of BC and improving timely access to appropriate treatments represent key approaches to achieving better treatment outcomes.
Keywords: Breast cancer treatment; Breast neoplasms; Cancer recurrence; Disease-free survival; Low-income countries; Prognostic factors.
© 2022 The Authors.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- DeSantis C.E., Bray F., Ferlay J., Lortet-Tieulent J., Anderson B.O., Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495–1506. - PubMed
-
- Elhassan M.M.A. Access to treatment for gynaecological malignancies in Sudan. S Afr J Gynaecol Oncol. 2018;10(2):21–23.
-
- Mariani-Costantini R., Elhassan M.M.A., Aceto G.M., Mohamedani A.A., Awadelkarim K.D. Epidemiology, pathology, management and open challenges of breast cancer in Central Sudan: a prototypical limited resource African setting. Breast Cancer-From Biol Med. 2017 doi: 10.5772/67175. - DOI
LinkOut - more resources
Full Text Sources
